Carcinoma, Small Cell

Oncology
1
Pipeline Programs
2
Companies
2
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
1
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

2 companies ranked by most advanced pipeline stage

Boehringer Ingelheim
Boehringer IngelheimINGELHEIM, Germany
1 program
1
BI 2536Phase 21 trial
Active Trials
NCT00412880Completed23Est. Jun 2008
AstraZeneca
AstraZenecaCAMBRIDGE, United Kingdom
1 program
IMFINZI Study in Patients With Extensive Stage Small Cell Lung CancerN/A1 trial
Active Trials
NCT04854590Completed248Est. Jul 2023

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
Boehringer IngelheimBI 2536
AstraZenecaIMFINZI Study in Patients With Extensive Stage Small Cell Lung Cancer

Clinical Trials (2)

Total enrollment: 271 patients across 2 trials

BI 2536 Second Line Monotherapy in SCLC

Start: Feb 2007Est. completion: Jun 200823 patients
Phase 2Completed
NCT04854590AstraZenecaIMFINZI Study in Patients With Extensive Stage Small Cell Lung Cancer

IMFINZI Study in Patients With Extensive Stage Small Cell Lung Cancer

Start: Apr 2021Est. completion: Jul 2023248 patients
N/ACompleted

Related Jobs in Oncology

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

2 companies competing in this space